The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers
Abstract
Altered expression of RNA binding proteins might contribute to cancer development. This study reveals the functional implications and clinical relevance of FXR1, an RNA binding protein, in non-small cell lung cancer (NSCLC). Our results demonstrate that FXR1 promotes tumor progression by regulating two other oncogenes within the same chromosome 3q amplicon. To drive tumor progression, FXR1 forms a new complex with protein kinase C, iota, and posttranscriptionally stabilizes the expression of epithelial cell transforming 2. We show that increased FXR1 expression in NSCLC is a candidate biomarker predictive of poor survival and might represent a novel therapeutic target. In addition, FXR1 expression correlates with poor clinical outcome in multiple human cancers, suggesting broader implications of this RNA binding protein in cancer progression.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 02, 2015
- Source ID
- 10.1073/pnas.1421975112
Entities
People
- Allan Espinosa
- Bradford K. Harris
- Fredrick T. Harris
- Heidi Chen
- Jing Wang
- Jun Qian
- Megan D. Hoeksema
- Mohamed Hassanein
- Pengcheng Lu
- Pierre P. Massion
- Rosana Eisenberg
- S. M. Jamshedur Rahman
- Xiangming Ji
- Yong Zou
Organizations
- Congressionally Directed Medical Research Programs
- Meharry Medical College
- National Cancer Institute
- Vanderbilt University
- Vanderbilt University School of Medicine